← Back to Search

Corticosteroid

Dexamethasone for Non-Small Cell Lung Cancer

N/A

Waitlist Available

Led By Anthony Shields

Research Sponsored by Barbara Ann Karmanos Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 6-9

Awards & highlights

No Placebo-Only Group

Summary

This trial studies the effects of dexamethasone, a steroid medication, in patients with non-small cell lung cancer that hasn't responded to other treatments. The medication may change how the cancer cells grow, and doctors use special imaging tests to monitor these changes. Dexamethasone has been shown to inhibit the growth of non-small cell lung cancer cells and affect their development.

Eligible Conditions

Lung Cancer
Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 6-9

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 6-9

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 6-9 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in tumor SUVmax assessed by 18F-FLT PET imaging

Secondary study objectives

Dexamethasone withdrawal as measured by changes in tumor FLT retention

Side effects data

From 2013 Phase 4 trial • 122 Patients • NCT01474915

Deep Vein Thrombosis

Cerebrospinal fluid leak

Fever

100%

80%

60%

40%

20%

Study treatment Arm

Ondansetron

Aprepitant

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (dexamethasone, 18F-FLT PET)Experimental Treatment4 Interventions

Patients receive dexamethasone PO BID on days 1-5. Patients undergo 3 18F-FLT PET scans. One scan within 7 days prior to the start of dexamethasone, one scan on day 3 after the 5th dose of dexamethasone, and one scan 6-9 days after the last dose of dexamethasone.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Positron Emission Tomography

2011

Completed Phase 2

~2200

Dexamethasone

2007

Completed Phase 4

~2650